Document is current
Any future updates will be listed below
-
Authors
Krishna, Anagha
Meynert, Alison https://orcid.org/0000-0001-5839-1751
Dolt, Karamjit Singh https://orcid.org/0000-0002-0584-7505
Kelder, Martijn
Mesropian, Agavni https://orcid.org/0000-0002-0604-4755
Ewing, Ailith https://orcid.org/0000-0002-2272-1277
Brouwers, Conny
Claassens, Jill WC
Linssen, Margot M. https://orcid.org/0000-0002-9157-1073
Sheraz, Shahida
Taylor, Gillian CA
Gautier, Philippe
Ferrer-Vaquer, Anna
Grimes, Graeme
Becher, Hannes
Silk, Ryan https://orcid.org/0000-0001-6421-1294
Gris-Oliver, Albert https://orcid.org/0000-0003-1802-9541
Pinyol, Roser
Semple, Colin A.
Kendall, Timothy J. https://orcid.org/0000-0002-4174-2786
Bird, Thomas Graham https://orcid.org/0000-0002-6120-1581
Hadjantonakis, Anna-Katerina
Marsh, Joseph A. https://orcid.org/0000-0003-4132-0628
Llovet, Josep M.
Hohenstein, Peter https://orcid.org/0000-0001-8548-4734
Wood, Andrew J. https://orcid.org/0000-0002-0653-2070
Ozdemir, Derya D. https://orcid.org/0000-0003-3486-0044
- License Information
-
More Information
Article History
Received: 16 August 2023
Accepted: 17 December 2025
First Online: 2 February 2026
Competing interests
: A.J.W. has received sponsored lecture fees from Altos Labs and serves as a consultant for Gemini Law. T.J.K. has served as a consultant or advisory board member for Resolution Therapeutics, Clinnovate Health, HistoIndex, Fibrofind, Kynos Therapeutics, Perspectum, Concept Life Sciences, Servier Laboratories, Taiho Oncology and Jazz Pharmaceuticals, and has received speakers’ fees from Servier Laboratories, Jazz Pharmaceuticals, AstraZeneca, HistoIndex and Incyte Corporation. J.L. has received research support from Genentech & Roche, consulting and sponsored lecture fees from Eisai, Merck, Roche, Genentech, AstraZeneca, Bayer Pharmaceuticals, AbbVie, Sanofi, Moderna, Glycotest, Exelixis and Boehringer Ingelheim, and is on the Data Safety Monitoring Board for Bristol Myers Squibb. All other authors declare no competing interests.
